{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:02:47Z","timestamp":1784422967667,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute severe ulcerative colitis (ASUC) is defined by the Truelove and Witts (TW) criteria. However, contemporary practice has shifted toward earlier admission and treatment escalation in advanced therapy\u2013experienced patients, resulting in a growing subgroup hospitalized for ASUC who do not fulfill TW (non-TW ASUC). This population remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective cohort study of all patients hospitalized for ASUC and treated with intravenous corticosteroids at a Danish tertiary center until 2023. The primary outcome of 1-year colectomy was assessed in an independent validation cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 109 included patients, 80 (73%) fulfilled TW criteria and 29 (27%) did not. Non-TW ASUC patients were less often female (28% vs 63%; P\u2009&amp;lt; .01), were less frequently steroid-na\u00efve (21% vs 48%; P\u2009&amp;lt; .05), and presented with lower systemic inflammation (C-reactive protein median 7\u2009mg\/L vs 34\u2009mg\/L; P\u2009&amp;lt; .001; hemoglobin 13.7 g\/dL vs 12.2\u2009g\/dL; P\u2009&amp;lt; .001; albumin 41 g\/L vs 38\u2009g\/L; P\u2009&amp;lt; .001). Colectomy-free survival and colectomy rates at 1, 3, and 12\u2009months were comparable between non-TW and TW ASUC (14% vs 10%, 21% vs 16%, and 29% vs 19%, respectively; P\u2009&amp;gt; .05). Results were similar in the validation cohort (n \u2009=\u200943). Medical rescue therapy use, tumor necrosis factor inhibitor exposure, and readmission rates through 1\u2009year did not differ significantly. Prognostic indices (Ho, Lindgren, Travis) similarly identified high-risk patients across both groups. Non-TW patients had shorter hospital stay (mean 6.5 days vs 8.6\u2009days; P\u2009&amp;lt; .01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Non-TW ASUC shows a disease course and outcomes comparable to TW ASUC, underscoring an equally severe and comparable condition. These findings emphasize a need to broaden ASUC definitions to reflect contemporary practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf323","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:03:34Z","timestamp":1765544614000},"page":"972-981","source":"Crossref","is-referenced-by-count":2,"title":["Acute severe ulcerative colitis without systemic toxicity: A retrospective multicenter cohort study suggesting refining the definition of acute severe ulcerative colitis"],"prefix":"10.1093","volume":"32","author":[{"given":"Frederik","family":"\u00d8rtoft","sequence":"first","affiliation":[{"name":"Department of Medical Gastroenterology, Odense University Hospital , Odense,","place":["Denmark"]},{"name":"Research Unit of Medical Gastroenterology, Department of Clinical Research, University of Southern Denmark , Odense,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde Jepsen","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology, Odense University Hospital , Odense,","place":["Denmark"]},{"name":"Research Unit of Medical Gastroenterology, Department of Clinical Research, University of Southern Denmark , Odense,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-6572","authenticated-orcid":false,"given":"Jens","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology, Odense University Hospital , Odense,","place":["Denmark"]},{"name":"Research Unit of Medical Gastroenterology, Department of Clinical Research, University of Southern Denmark , Odense,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-4212","authenticated-orcid":false,"given":"Casper","family":"Steenholdt","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology, Odense University Hospital , Odense,","place":["Denmark"]},{"name":"Research Unit of Medical Gastroenterology, Department of Clinical Research, University of Southern Denmark , Odense,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ainsworth","sequence":"additional","affiliation":[{"name":"Department of Medical Gastroenterology, Odense University Hospital , Odense,","place":["Denmark"]},{"name":"Research Unit of Medical Gastroenterology, Department of Clinical Research, University of Southern Denmark , Odense,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026050317370839100_izaf323-B1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bpg.2018.05.007","article-title":"Acute severe ulcerative colitis: state of the art treatment","volume":"32-33","author":"Gisbert","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026050317370839100_izaf323-B2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ecco-jcc\/jjy154","article-title":"Natural disease course of ulcerative colitis during the first five years of follow-up in a european population-based inception Cohort-An Epi-IBD study","volume":"13","author":"Burisch","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026050317370839100_izaf323-B3","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1053\/j.gastro.2022.07.062","article-title":"The rising burden of inflammatory bowel disease in denmark over two decades: a nationwide cohort study","volume":"163","author":"Agrawal","year":"2022","journal-title":"Gastroenterology"},{"key":"2026050317370839100_izaf323-B4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"2026050317370839100_izaf323-B5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026050317370839100_izaf323-B6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5009\/gnl220017","article-title":"Acute severe ulcerative colitis: optimal strategies for drug therapy","volume":"17","author":"Nakase","year":"2023","journal-title":"Gut Liver"},{"key":"2026050317370839100_izaf323-B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022"},{"key":"2026050317370839100_izaf323-B8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","article-title":"Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","author":"Ho","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2026050317370839100_izaf323-B9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/00042737-199810000-00003","article-title":"Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis","volume":"10","author":"Lindgren","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026050317370839100_izaf323-B10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis","year":"1996","journal-title":"Gut"},{"key":"2026050317370839100_izaf323-B11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.cgh.2024.10.029","article-title":"Acute severe ulcerative colitis: an international delphi consensus on clinical trial design and endpoints","volume":"23","author":"Honap","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026050317370839100_izaf323-B12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2026050317370839100_izaf323-B13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026050317370839100_izaf323-B14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050317370839100_izaf323-B15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000518131","article-title":"Assessment of endoscopic disease activity in ulcerative colitis: is simplicity the ultimate sophistication?","volume":"7","author":"Sharara","year":"2022","journal-title":"Inflamm Intest Dis"},{"key":"2026050317370839100_izaf323-B16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/ecco-jcc\/jjaa265","article-title":"Predicting outcome in acute severe colitis-controversies in clinical practice in 2021","volume":"15","author":"Gupta","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026050317370839100_izaf323-B17","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14060580","article-title":"Current management of acute severe ulcerative colitis: new insights on the surgical approaches","volume":"14","author":"Lauricella","year":"2024","journal-title":"J Pers Med"},{"key":"2026050317370839100_izaf323-B18","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.3390\/jcm13237446","article-title":"Recent advances in the management of acute severe ulcerative colitis","volume":"13","author":"Ong Ming San","year":"2024","journal-title":"J Clin Med"},{"key":"2026050317370839100_izaf323-B19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/ecco-jcc\/jjac083","article-title":"Early intestinal ultrasound predicts intravenous corticosteroid response in hospitalised patients with severe ulcerative colitis","volume":"16","author":"Ilvemark","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026050317370839100_izaf323-B20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026050317370839100_izaf323-B21","doi-asserted-by":"crossref","first-page":"jjaf021","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026050317370839100_izaf323-B22","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026050317370839100_izaf323-B23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ibd\/izae191","article-title":"Upadacitinib for acute severe ulcerative colitis: a systematic review","volume":"31","author":"Damianos","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026050317370839100_izaf323-B24","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2026050317370839100_izaf323-B25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","article-title":"Assessing severity of disease in patients with ulcerative colitis","volume":"49","author":"Pabla","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"2026050317370839100_izaf323-B26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"2026050317370839100_izaf323-B27","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/5\/972\/66866687\/izaf323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/5\/972\/66866687\/izaf323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:37:14Z","timestamp":1777844234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/5\/972\/8475570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf323","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,12]]}}}